120 related articles for article (PubMed ID: 24594769)
1. [Rechallenge of everolimus for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report].
Utsunomiya N; Kono Y; Matsumoto K; Matsumoto T; Nakagawa A; Tsunemori H; Okada T; Muguruma K; Kawakita M
Hinyokika Kiyo; 2014 Jan; 60(1):25-8. PubMed ID: 24594769
[TBL] [Abstract][Full Text] [Related]
2. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.
Mizuno R; Asano K; Mikami S; Nagata H; Kaneko G; Oya M
Jpn J Clin Oncol; 2012 May; 42(5):442-6. PubMed ID: 22438405
[TBL] [Abstract][Full Text] [Related]
3. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma.
Saito Y; Nagayama M; Miura Y; Ogushi S; Suzuki Y; Noro R; Minegishi Y; Kimura G; Kondo Y; Gemma A
Jpn J Clin Oncol; 2013 May; 43(5):559-62. PubMed ID: 23423809
[TBL] [Abstract][Full Text] [Related]
4. Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy.
Saito Y; Kunugi S; Suzuki Y; Narita K; Miura Y; Minegishi Y; Kimura G; Kondo Y; Azuma A; Fukuda Y; Gemma A
Intern Med; 2013; 52(2):263-7. PubMed ID: 23318860
[TBL] [Abstract][Full Text] [Related]
5. [mTOR inhibitors].
Oya M
Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
[TBL] [Abstract][Full Text] [Related]
6. [Spontaneous Remission of Everolimus-Induced Interstitial Lung Disease in Metastatic Renal Cell Carcinoma : An Autopsy Case Report].
Kurokawa M; Naito S; Ichiyanagi O; Kabasawa T; Kurota Y; Sakurai T; Nishida H; Kawazoe H; Kato T; Nagaoka A; Yamakawa M; Tsuchiya N
Hinyokika Kiyo; 2017 Sep; 63(9):377-380. PubMed ID: 28992668
[TBL] [Abstract][Full Text] [Related]
7. Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma.
Akata K; Yatera K; Ishimoto H; Kozaki M; Yamasaki K; Nagata S; Nishida C; Yoshida T; Kawanami T; Matsumoto T; Mukae H
Intern Med; 2011; 50(24):3013-7. PubMed ID: 22185995
[TBL] [Abstract][Full Text] [Related]
8. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice.
Nozawa M; Nonomura N; Ueda T; Nishimura K; Kanayama HO; Miki T; Nakatani T; Tomita Y; Azuma H; Yoshioka T; Tsujihata M; Uemura H
Jpn J Clin Oncol; 2013 Nov; 43(11):1132-8. PubMed ID: 23999768
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
10. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
Cetin B; Coskun U; Yildiz R; Buyukberber S; Baykara M; Benekli M
J Oncol Pharm Pract; 2011 Sep; 17(3):274-8. PubMed ID: 20215482
[TBL] [Abstract][Full Text] [Related]
11. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
12. [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
Büchler T; Dusek L; Fínek J; Poprach A; Budnáková D; Kandrnal V; Jarkovský J; Bortlícek Z; Klimes D; Abrahámová J; Vyzula R
Klin Onkol; 2011; 24(5):389-92. PubMed ID: 22070021
[TBL] [Abstract][Full Text] [Related]
13. Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor.
Rothermundt C; Gillessen S
J Clin Oncol; 2013 Feb; 31(5):e57-8. PubMed ID: 23295800
[No Abstract] [Full Text] [Related]
14. Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
Roca S; Quivy A; Gross-Goupil M; Bernhard JC; De Clermont H; Ravaud A
Acta Oncol; 2011 Oct; 50(7):1135-6. PubMed ID: 21726178
[No Abstract] [Full Text] [Related]
15. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
[TBL] [Abstract][Full Text] [Related]
16. [Role of mTOR inhibition in the treatment of metastatic renal cell carcinoma].
Mizuno R; Miyajima A; Oya M
Nihon Jinzo Gakkai Shi; 2012; 54(5):581-5. PubMed ID: 22991836
[No Abstract] [Full Text] [Related]
17. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
[TBL] [Abstract][Full Text] [Related]
18. [Everolimus (RAD001/Afinitor) in the treatment of metastatic cell carcinoma].
Gennigens C; Sautois B; Jerusalem G
Rev Med Liege; 2010 Apr; 65(4):212-6. PubMed ID: 20499824
[TBL] [Abstract][Full Text] [Related]
19. [Management of side effects of everolimus treatment for metastatic renal cell carcinoma].
Mikami K; Hongo F; Miki T
Hinyokika Kiyo; 2012 Nov; 58(11):647-50. PubMed ID: 23254794
[TBL] [Abstract][Full Text] [Related]
20. Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma.
Loron MC; Grange S; Guerrot D; Di Fiore F; Freguin C; Hanoy M; Le Roy F; Poussard G; Etienne I; Legallicier B; Pfister C; Godin M; Bertrand D
J Clin Oncol; 2015 Mar; 33(8):e45-7. PubMed ID: 24638002
[No Abstract] [Full Text] [Related]
[Next] [New Search]